Immunostimulatory combinations: designing the next generation of vaccine adjuvants
暂无分享,去创建一个
[1] J. Berzofsky,et al. Differential effects of CD40 ligand/trimer stimulation on the ability of dendritic cells to replicate and transmit HIV infection: evidence for CC-chemokine-dependent and -independent mechanisms. , 1999, Journal of immunology.
[2] F. Di Virgilio,et al. The P2X7 receptor: a key player in IL-1 processing and release , 2007, The Journal of Immunology.
[3] E. Kleinerman,et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. Zinkernagel,et al. Intralymphatic immunization enhances DNA vaccination , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[5] Jasmyn A. Dunn,et al. Differences in Macrophage Activation by Bacterial DNA and CpG-Containing Oligonucleotides1 , 2005, The Journal of Immunology.
[6] P. Coulie,et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[7] J. Ceuppens,et al. CD40L‐Induced IL‐12 Production is Further Enhanced by the Th2 Cytokines IL‐4 and IL‐13 , 2001, Scandinavian journal of immunology.
[8] Simon C Watkins,et al. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. , 2005, Cancer research.
[9] E. Raz,et al. Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization , 1996, Science.
[10] G. Trinchieri,et al. The Interleukin 12 P40 Gene Promoter Is Primed by Interferon ~/in Monocytic Cells , 1996 .
[11] Dong Yu,et al. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[12] H. Matsue,et al. Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine , 2002, Nature Biotechnology.
[13] B. Pulendran. Variegation of the Immune Response with Dendritic Cells and Pathogen Recognition Receptors1 , 2005, The Journal of Immunology.
[14] Shizuo Akira,et al. Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA , 2004, Science.
[15] P. Österlund,et al. TNF-α and IFN-α enhance influenza-A-virus-induced chemokine gene expression in human A549 lung epithelial cells , 2006 .
[16] K. Ishii,et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses , 2006, Nature.
[17] E. Raz,et al. Antigen–immunostimulatory oligonucleotide conjugates: mechanisms and applications , 2004, Immunological reviews.
[18] T. Giese,et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. , 2001, European journal of immunology.
[19] R. Koup,et al. Toll-Like Receptor Ligands Modulate Dendritic Cells to Augment Cytomegalovirus- and HIV-1-Specific T Cell Responses 1 , 2003, The Journal of Immunology.
[20] R. Steinman,et al. Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells , 2005, The Journal of experimental medicine.
[21] T. So,et al. Tumor Necrosis Factor/Tumor Necrosis Factor Receptor Family Members That Positively Regulate Immunity , 2006, International journal of hematology.
[22] B. Rouse,et al. Rescue of memory CD8+ T cell reactivity in peptide/TLR9 ligand immunization by codelivery of cytokines or CD40 ligation. , 2005, Virology.
[23] R. Steinman,et al. The Linkage of Innate to Adaptive Immunity via Maturing Dendritic Cells In Vivo Requires CD40 Ligation in Addition to Antigen Presentation and CD80/86 Costimulation , 2004, The Journal of experimental medicine.
[24] S. Sakaguchi,et al. Control of Foxp3+ CD25+CD4+ regulatory cell activation and function by dendritic cells. , 2004, International immunology.
[25] Michael Sixt,et al. The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. , 2005, Immunity.
[26] D. Hume,et al. IFN-gamma primes macrophage responses to bacterial DNA. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[27] Lieping Chen,et al. Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules , 2006, Cancer Immunology, Immunotherapy.
[28] E. Jaffee,et al. OX40 Costimulation Synergizes with GM-CSF Whole-Cell Vaccination to Overcome Established CD8+ T Cell Tolerance to an Endogenous Tumor Antigen1 , 2006, The Journal of Immunology.
[29] S. Wahl,et al. TGF‐β: the perpetrator of immune suppression by regulatory T cells and suicidal T cells , 2004, Journal of leukocyte biology.
[30] M. Norcross,et al. Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes. , 1995, Blood.
[31] M. Chamaillard,et al. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. , 2005, Annual review of biochemistry.
[32] T. Fry,et al. Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. , 2005, The Journal of clinical investigation.
[33] K. Tracey,et al. High Mobility Group Box Protein 1: An Endogenous Signal for Dendritic Cell Maturation and Th1 Polarization , 2004, The Journal of Immunology.
[34] T. Nakahata,et al. Differential Requirement for the CD40-CD154 Costimulatory Pathway during Th Cell Priming by CD8α+ and CD8α− Murine Dendritic Cell Subsets1 , 2004, The Journal of Immunology.
[35] Kendall A. Smith,et al. Contrasting Effects of Low-Dose IL-2 on Vaccine-Boosted Simian Immunodeficiency Virus (SIV)-Specific CD4+ and CD8+ T Cells in Macaques Chronically Infected with SIVmac251 , 2005, The Journal of Immunology.
[36] R. Offringa,et al. C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L , 2005, Nature chemical biology.
[37] Edgar Schmitt,et al. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. , 2006, Blood.
[38] T. Whittall,et al. CD40 is a cellular receptor mediating mycobacterial heat shock protein 70 stimulation of CC-chemokines. , 2001, Immunity.
[39] T. Whittall,et al. Functional domains of HSP70 stimulate generation of cytokines and chemokines, maturation of dendritic cells and adjuvanticity. , 2004, Biochemical Society transactions.
[40] D. Strayer,et al. Preclinical studies with Ampligen (mismatched double-stranded RNA). , 1985, Journal of Biological Response Modifiers.
[41] C. Ahonen,et al. Combined TLR and CD40 Triggering Induces Potent CD8+ T Cell Expansion with Variable Dependence on Type I IFN , 2004, The Journal of experimental medicine.
[42] A. Aderem,et al. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[43] P. Leclerc,et al. Differential effect of agonistic anti-CD40 on human mature and immature dendritic cells: the Janus face of anti-CD40. , 2005, Blood.
[44] S. Akira,et al. Toll-like receptors in innate immunity. , 2004, International immunology.
[45] S. Akira,et al. Dendritic Cell Maturation Induced by Muramyl Dipeptide (MDP) Derivatives: Monoacylated MDP Confers TLR2/TLR4 Activation1 , 2005, The Journal of Immunology.
[46] Tomohiro Watanabe,et al. NOD2 is a negative regulator of Toll-like receptor 2–mediated T helper type 1 responses , 2004, Nature Immunology.
[47] N. Bhardwaj,et al. Plasmacytoid Dendritic Cells: Linking Innate and Adaptive Immunity , 2005, Journal of Virology.
[48] S. Rybak,et al. Ribonuclease is partly responsible for the HIV-1 inhibitory effect activated by HLA alloantigen recognition , 2003, AIDS.
[49] J. Kim,et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. , 1997, Journal of immunology.
[50] G. Belz,et al. Helper T cells, dendritic cells and CTL Immunity , 2004, Immunology and cell biology.
[51] S. Akira,et al. Toll-like receptors: critical proteins linking innate and acquired immunity , 2001, Nature Immunology.
[52] P. Greenberg,et al. Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. , 2004, Immunity.
[53] P. Beverley,et al. Lipopolysaccharide Modulation of Dendritic Cells Is Insufficient to Mature Dendritic Cells to Generate CTLs from Naive Polyclonal CD8+ T Cells In Vitro, Whereas CD40 Ligation Is Essential1 , 2001, The Journal of Immunology.
[54] E. Gilboa,et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. , 2005, The Journal of clinical investigation.
[55] E. Gilboa,et al. Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. , 1998, Cancer research.
[56] K. Hunt,et al. Synergistic enhancement of Toll‐like receptor responses by NOD1 activation , 2005, European journal of immunology.
[57] Renate Kunert,et al. Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies , 2005, Science.
[58] P. Payette,et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities , 2004, European journal of immunology.
[59] A. Hill,et al. Anti-CD25 Antibody Enhancement of Vaccine-Induced Immunogenicity: Increased Durable Cellular Immunity with Reduced Immunodominance1 , 2005, The Journal of Immunology.
[60] G. Trinchieri,et al. Interleukin‐10 in viral diseases and cancer: exiting the labyrinth? , 2004, Immunological reviews.
[61] Shizuo Akira,et al. TLR signaling pathways. , 2004, Seminars in immunology.
[62] J. Kim,et al. Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines. , 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[63] Ruslan Medzhitov,et al. Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells , 2003, Science.
[64] S. Kingsmore,et al. Human Ribonuclease A Superfamily Members, Eosinophil-Derived Neurotoxin and Pancreatic Ribonuclease, Induce Dendritic Cell Maturation and Activation1 , 2004, The Journal of Immunology.
[65] C. Drake,et al. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. , 2006, Blood.
[66] L. Jacobs,et al. Nucleotide-Binding Oligomerization Domain-2 Modulates Specific TLR Pathways for the Induction of Cytokine Release 1 , 2005, The Journal of Immunology.
[67] Mario Roederer,et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. , 2006, Blood.
[68] S. Kaufmann,et al. Regulatory CD4+CD25+ T Cells Restrict Memory CD8+ T Cell Responses , 2002, The Journal of experimental medicine.
[69] N. Letvin,et al. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses , 2004, Immunological reviews.
[70] Persephone Borrow,et al. Viral infection switches non-plasmacytoid dendritic cells into high interferon producers , 2003, Nature.
[71] Li Li,et al. Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 , 2003, The Journal of experimental medicine.
[72] L. Weinberger,et al. Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virus–infected Macaques , 1999, The Journal of experimental medicine.
[73] F. Martinon,et al. Inflammatory Caspases Linking an Intracellular Innate Immune System to Autoinflammatory Diseases , 2004, Cell.
[74] A. Craiu,et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. , 1998, Journal of immunology.
[75] G. Trinchieri,et al. In vivo manipulation of dendritic cell migration and activation to elicit antitumour immunity. , 2004, Novartis Foundation symposium.
[76] E. Raz,et al. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism , 2000, Nature Biotechnology.
[77] S. Akira,et al. Synergistic Effect of Muramyldipeptide with Lipopolysaccharide or Lipoteichoic Acid To Induce Inflammatory Cytokines in Human Monocytic Cells in Culture , 2001, Infection and Immunity.
[78] G. Trinchieri,et al. Reversal of Tumor-induced Dendritic Cell Paralysis by CpG Immunostimulatory Oligonucleotide and Anti–Interleukin 10 Receptor Antibody , 2002, The Journal of experimental medicine.
[79] H. S. Warren,et al. Toll-like receptors. , 2005, Critical care medicine.
[80] G. Trinchieri,et al. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. , 2005, Cancer research.
[81] J. Bae,et al. 4‐1BB‐dependent inhibition of immunosuppression by activated CD4+CD25+ T cells , 2004, Journal of leukocyte biology.
[82] Francesco Bertoni,et al. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1–polarizing program in dendritic cells , 2005, Nature Immunology.
[83] P. Borrow,et al. CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CD8+ CTL response , 1996, The Journal of experimental medicine.
[84] L. Chess,et al. Regulation of immune responses by T cells. , 2006, The New England journal of medicine.
[85] A. Palucka,et al. Dendritic cells as therapeutic vaccines against cancer , 2005, Nature Reviews Immunology.
[86] M. Merad,et al. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. , 2004, The Journal of clinical investigation.
[87] B. Wüthrich,et al. Direct intralymphatic injection of peptide vaccines enhances immunogenicity , 2005, European journal of immunology.
[88] T. Waldmann,et al. Coimmunization with an Optimized IL-15 Plasmid Results in Enhanced Function and Longevity of CD8 T Cells That Are Partially Independent of CD4 T Cell Help3 , 2005, The Journal of Immunology.
[89] G. Trinchieri,et al. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells , 1996, The Journal of experimental medicine.
[90] B. Rouse,et al. Molecular adjuvants for mucosal immunity , 2004, Immunological reviews.
[91] I. Otterness,et al. ATP induces the release of IL-1 from LPS-primed cells in vivo. , 1995, Journal of immunology.
[92] A. Forbes,et al. Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn’s disease , 2005, Gut.
[93] T. Watts,et al. TNF/TNFR family members in costimulation of T cell responses. , 2005, Annual review of immunology.
[94] B. Beutler,et al. TLR4 as the mammalian endotoxin sensor. , 2002, Current topics in microbiology and immunology.
[95] W. Fanslow,et al. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40 , 1993, The Journal of experimental medicine.
[96] S. Santra,et al. Plasmid Chemokines and Colony-Stimulating Factors Enhance the Immunogenicity of DNA Priming-Viral Vector Boosting Human Immunodeficiency Virus Type 1 Vaccines , 2003, Journal of Virology.
[97] Weiyi Peng,et al. Toll-Like Receptor 8-Mediated Reversal of CD4+ Regulatory T Cell Function , 2005, Science.
[98] M. Levings,et al. Human CD4+ T Cells Express TLR5 and Its Ligand Flagellin Enhances the Suppressive Capacity and Expression of FOXP3 in CD4+CD25+ T Regulatory Cells1 , 2005, The Journal of Immunology.
[99] J. Bertin,et al. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. , 2006, Immunity.
[100] Moses Rodriguez,et al. Immunotherapeutic Potential of B7-DC (PD-L2) Cross-Linking Antibody In Conferring Antitumor Immunity , 2004, Cancer Research.
[101] C. Arteaga,et al. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. , 2003, Cancer research.
[102] Michael Karin,et al. Intracellular pattern recognition receptors in the host response , 2006, Nature.
[103] K. Black,et al. Small interference RNA modulation of IL‐10 in human monocyte‐derived dendritic cells enhances the Th1 response , 2004, European journal of immunology.
[104] T. Utsugi,et al. CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. , 2003, Immunity.
[105] Stefan Bauer,et al. Endosomal Translocation of Vertebrate DNA Activates Dendritic Cells via TLR9-Dependent and -Independent Pathways 1 , 2005, The Journal of Immunology.
[106] Stephen Shaw,et al. Cords, channels, corridors and conduits: critical architectural elements facilitating cell interactions in the lymph node cortex , 1997, Immunological reviews.
[107] J. Berzofsky,et al. A push–pull approach to maximize vaccine efficacy: Abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[108] D. Montefiori,et al. IL-12/GM-CSF coadministration in an SIV DNA prime/protein boost protocol enhances Gag-specific T cells but not virus-specific neutralizing antibodies in rhesus macaques. , 2003, AIDS research and human retroviruses.
[109] Bryan R. G. Williams,et al. Synergistic Activation of Innate Immunity by Double-Stranded RNA and CpG DNA Promotes Enhanced Antitumor Activity , 2004, Cancer Research.
[110] Todd M. Allen,et al. HIV evolution: CTL escape mutation and reversion after transmission , 2004, Nature Medicine.
[111] R. Vile,et al. Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. , 2003, Cancer research.
[112] S. Müller,et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells , 2004, EMBO reports.
[113] J. Turk,et al. Effect of anticancer drugs on the release of interleukin-6 in vitro , 2005, Cancer Immunology, Immunotherapy.
[114] S. Akira,et al. Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway , 2003, Science.
[115] C. Junghans,et al. Cytokine and Ig‐production by CG‐containing sequences with phosphorodiester backbone and dumbbell‐shape , 2006, Allergy.
[116] B. Walker,et al. The Role of CD4+ T Cell Help and CD40 Ligand in the In Vitro Expansion of HIV-1-Specific Memory Cytotoxic CD8+ T Cell Responses , 2000, The Journal of Immunology.
[117] Wayne C Koff,et al. HIV vaccine design and the neutralizing antibody problem , 2004, Nature Immunology.
[118] G. Zhu,et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. , 2005, Cancer research.
[119] J. Ting,et al. Cutting Edge: CATERPILLER: A Large Family of Mammalian Genes Containing CARD, Pyrin, Nucleotide-Binding, and Leucine-Rich Repeat Domains1 , 2002, The Journal of Immunology.
[120] M. Bachmann,et al. CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. , 2005, Immunity.
[121] G. Nabel,et al. Effects of Antigen and Genetic Adjuvants on Immune Responses to Human Immunodeficiency Virus DNA Vaccines in Mice , 2002, Journal of Virology.
[122] A. Rakhmilevich,et al. Synergistic Activation of Macrophages via CD40 and TLR9 Results in T Cell Independent Antitumor Effects1 , 2006, The Journal of Immunology.
[123] J. Andersen,et al. TLR11 Activation of Dendritic Cells by a Protozoan Profilin-Like Protein , 2005, Science.
[124] P. Manley,et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. , 1989, Journal of the National Cancer Institute.
[125] D. Golenbock,et al. Toll-like Receptor 2 Functions as a Pattern Recognition Receptor for Diverse Bacterial Products* , 1999, The Journal of Biological Chemistry.
[126] G. Trinchieri,et al. Human TLR10 Is a Functional Receptor, Expressed by B Cells and Plasmacytoid Dendritic Cells, Which Activates Gene Transcription through MyD881 , 2005, The Journal of Immunology.
[127] G. Karupiah,et al. Cutting Edge: Conventional CD8α+ Dendritic Cells Are Generally Involved in Priming CTL Immunity to Viruses 1 , 2004, The Journal of Immunology.
[128] Jongdae Lee,et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[129] S. Lemon,et al. Distinct Poly(I-C) and Virus-activated Signaling Pathways Leading to Interferon-β Production in Hepatocytes* , 2005, Journal of Biological Chemistry.
[130] R. Schreiber,et al. IFN-γ Controls the Generation/Activation of CD4+CD25+ Regulatory T Cells in Antitumor Immune Response1 , 2005, The Journal of Immunology.
[131] S. Buchbinder,et al. CD40 ligand and IFN‐γ synergistically restore IL‐12 production in HIV‐infected patients , 1998 .
[132] J. Banchereau,et al. Activation of human dendritic cells through CD40 cross-linking , 1994, The Journal of experimental medicine.
[133] J. Oppenheim,et al. Alarmins: chemotactic activators of immune responses. , 2005, Current opinion in immunology.
[134] B. Pulendran. Modulating vaccine responses with dendritic cells and Toll‐like receptors , 2004, Immunological reviews.
[135] M. Colombo,et al. Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. , 2005, Blood.
[136] K. Sugamura,et al. Distinct Roles for the OX40-OX40 Ligand Interaction in Regulatory and Nonregulatory T Cells1 , 2004, The Journal of Immunology.
[137] S. Akira,et al. Muramyl Dipeptide Enhances Osteoclast Formation Induced by Lipopolysaccharide, IL-1α, and TNF-α through Nucleotide-Binding Oligomerization Domain 2-Mediated Signaling in Osteoblasts1 , 2005, The Journal of Immunology.
[138] D. Weiner,et al. Co-immunization with plasmid IL-12 generates a strong T-cell memory response in mice. , 2004, Vaccine.
[139] T. Berg,et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection , 2005, Hepatology.
[140] James W. Young,et al. Human Dendritic Cells: Potent Antigen-Presenting Cells at the Crossroads of Innate and Adaptive Immunity1 , 2005, The Journal of Immunology.
[141] F. Martinon,et al. Identification of Bacterial Muramyl Dipeptide as Activator of the NALP3/Cryopyrin Inflammasome , 2004, Current Biology.
[142] Gabrielle T Belz,et al. Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity , 2004, Nature Immunology.
[143] F. Yarovinsky,et al. Mouse Cathelin-Related Antimicrobial Peptide Chemoattracts Leukocytes Using Formyl Peptide Receptor-Like 1/Mouse Formyl Peptide Receptor-Like 2 as the Receptor and Acts as an Immune Adjuvant1 , 2005, The Journal of Immunology.
[144] S. Akira,et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway , 2002, Nature Immunology.
[145] J. Ahlers. A push-pull approach to maximize vaccine efficacy : abrogating suppression with an IL-13 inhibitor while augmenting help with GM-CSF and CD40L , 2002 .
[146] V. Mehta,et al. ATP-stimulated Release of Interleukin (IL)-1β and IL-18 Requires Priming by Lipopolysaccharide and Is Independent of Caspase-1 Cleavage* , 2001, The Journal of Biological Chemistry.
[147] A. Bowie,et al. TLR3 in antiviral immunity: key player or bystander? , 2005, Trends in immunology.
[148] A. Lanzavecchia,et al. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization , 2000, Nature Immunology.
[149] Shizuo Akira,et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses , 2004, Nature Immunology.
[150] J. Kirkwood,et al. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. , 2004, Cancer research.
[151] R. Kornbluth. An expanding role for CD40L and other tumor necrosis factor superfamily ligands in HIV infection. , 2002, Journal of hematotherapy & stem cell research.
[152] D. Busch,et al. Vaccination with Plasmid DNA Activates Dendritic Cells via Toll-Like Receptor 9 (TLR9) but Functions in TLR9-Deficient Mice 1 , 2003, The Journal of Immunology.
[153] M. Seman,et al. NAD-induced T cell death: ADP-ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 purinoceptor. , 2003, Immunity.
[154] K. Mittenbühler,et al. Triacyl-lipopentapeptide adjuvants: TLR2-dependent activation of macrophages and modulation of receptor-mediated cell activation by altering acyl-moieties. , 2004, International immunopharmacology.
[155] M. Braunstein,et al. The CATERPILLER Protein Monarch-1 Is an Antagonist of Toll-like Receptor-, Tumor Necrosis Factor α-, and Mycobacterium tuberculosis-induced Pro-inflammatory Signals* , 2005, Journal of Biological Chemistry.
[156] P. Sinha,et al. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression , 2005, Cancer Immunology, Immunotherapy.
[157] M. Kuroda,et al. Potent CD4+ T Cell Responses Elicited by a Bicistronic HIV-1 DNA Vaccine Expressing gp120 and GM-CSF1 , 2002, The Journal of Immunology.
[158] M. Bachmann,et al. Chemokines: more than just road signs , 2006, Nature Reviews Immunology.
[159] J. Berzofsky,et al. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. , 1997, Journal of immunology.
[160] Osamu Takeuchi,et al. Cell type-specific involvement of RIG-I in antiviral response. , 2005, Immunity.
[161] T. Luft,et al. IFN‐α enhances CD40 ligand‐mediated activation of immature monocyte‐derived dendritic cells , 2002 .
[162] R. Steinman,et al. Exploiting dendritic cells to improve vaccine efficacy. , 2002, The Journal of clinical investigation.
[163] S. Akira,et al. A Subset of Toll-Like Receptor Ligands Induces Cross-presentation by Bone Marrow-Derived Dendritic Cells1 , 2003, The Journal of Immunology.
[164] B. Beutler,et al. Inferences, questions and possibilities in Toll-like receptor signalling , 2004, Nature.
[165] H. Lyerly,et al. A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. , 2000, Blood.
[166] John Sidney,et al. Reversion of CTL escape–variant immunodeficiency viruses in vivo , 2004, Nature Medicine.
[167] S. Paul,et al. Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L , 2005, Cancer Gene Therapy.
[168] L. Notarangelo,et al. C4b-binding protein (C4BP) activates B cells through the CD40 receptor. , 2003, Immunity.
[169] F. Sallusto,et al. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells , 2000, Nature Immunology.
[170] J. Sprent,et al. Type I Interferon-mediated Stimulation of T Cells by CpG DNA , 1998, Journal of Experimental Medicine.
[171] T. Okazaki,et al. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4 , 2005, Nature Immunology.
[172] R. Steinman,et al. Intensified and protective CD4+ T cell immunity in mice with anti–dendritic cell HIV gag fusion antibody vaccine , 2006, The Journal of experimental medicine.
[173] S. Foster,et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid , 2003, Nature Immunology.
[174] Christophe Caux,et al. Tumour escape from immune surveillance through dendritic cell inactivation. , 2002, Seminars in cancer biology.
[175] I. Fidler,et al. Synergism between human recombinant gamma-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes. , 1985, Cancer research.
[176] Urs Christen,et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes , 2003, Nature.
[177] E. Raz,et al. IFN-αβ Promote Priming of Antigen-Specific CD8+ and CD4+ T Lymphocytes by Immunostimulatory DNA-Based Vaccines1 , 2002, The Journal of Immunology.
[178] S. Akira,et al. Cutting Edge: Preferentially the R-Stereoisomer of the Mycoplasmal Lipopeptide Macrophage-Activating Lipopeptide-2 Activates Immune Cells Through a Toll-Like Receptor 2- and MyD88-Dependent Signaling Pathway1 , 2000, The Journal of Immunology.
[179] J. Bertin,et al. Nod1 Detects a Unique Muropeptide from Gram-Negative Bacterial Peptidoglycan , 2003, Science.
[180] A. Sher,et al. CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. , 2000, Immunity.
[181] J. Nemunaitis,et al. GM-CSF gene-transduced tumor vaccines. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[182] C Caux,et al. Immunobiology of dendritic cells. , 2000, Annual review of immunology.
[183] P. Kalinski,et al. High-level IL-12 production by human dendritic cells requires two signals. , 1998, International immunology.
[184] P. Hwu,et al. Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen‐specific T lymphocytes , 2000, European journal of immunology.
[185] Richard A Flavell,et al. Transforming growth factor-beta regulation of immune responses. , 2006, Annual review of immunology.
[186] C. Benoist,et al. Initiation of Autoimmune Diabetes by Developmentally Regulated Presentation of Islet Cell Antigens in the Pancreatic Lymph Nodes , 1999, The Journal of experimental medicine.
[187] M. Hashida,et al. Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-β gene and poly I: poly C in a murine lung metastasis model , 2003, Cancer Gene Therapy.
[188] Tae Woo Kim,et al. Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. , 2005, Cancer research.
[189] D. Richman,et al. CD40 ligand (CD154) stimulation of macrophages to produce HIV-1-suppressive beta-chemokines. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[190] T. Whiteside,et al. In vitro effects of an acyltripeptide, FK565, on NK-cell activity, LAK-cell generation and cytokine production by human mononuclear cells. , 1989, Immunopharmacology.
[191] C. Papasian,et al. Bacterial DNA and Lipopolysaccharide Induce Synergistic Production of TNF-α Through a Post-Transcriptional Mechanism1 , 2001, The Journal of Immunology.
[192] A. Di Nardo,et al. Augmentation of Cutaneous Immune Responses by ATPγS: Purinergic Agonists Define a Novel Class of Immunologic Adjuvants1 , 2005, The Journal of Immunology.
[193] D. Montefiori,et al. Effect of CD8+ Lymphocyte Depletion on Virus Containment after Simian Immunodeficiency Virus SIVmac251 Challenge of Live Attenuated SIVmac239Δ3-Vaccinated Rhesus Macaques , 2005, Journal of Virology.
[194] A. Shaw,et al. Triggering TLR signaling in vaccination. , 2006, Trends in immunology.
[195] F. Mennechet,et al. Interferon-λ-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells , 2006 .
[196] J. Mascola,et al. Characterization of Antibody Responses Elicited by Human Immunodeficiency Virus Type 1 Primary Isolate Trimeric and Monomeric Envelope Glycoproteins in Selected Adjuvants , 2006, Journal of Virology.
[197] G. Hartmann,et al. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[198] T. Luft,et al. IL-1β Enhances CD40 Ligand-Mediated Cytokine Secretion by Human Dendritic Cells (DC): A Mechanism for T Cell-Independent DC Activation1 , 2002, The Journal of Immunology.
[199] D. Pardoll,et al. Persistent Toll-like receptor signals are required for reversal of regulatory T cell–mediated CD8 tolerance , 2004, Nature Immunology.
[200] R. Noelle,et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. , 2002, Cellular immunology.
[201] R. Hancock,et al. The Cationic Antimicrobial Peptide LL-37 Modulates Dendritic Cell Differentiation and Dendritic Cell-Induced T Cell Polarization , 2004, The Journal of Immunology.
[202] A. Enk,et al. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. , 2005, Cancer research.
[203] B. Kwon,et al. Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells. , 2006, International immunology.
[204] E. Leiter,et al. P2X7 Receptor-Dependent and -Independent T Cell Death Is Induced by Nicotinamide Adenine Dinucleotide1 , 2005, The Journal of Immunology.
[205] Alan Aderem,et al. Edinburgh Research Explorer Macrophages exposed continuously to lipopolysaccharide and other agonists that act via toll-like receptors exhibit a sustained and additive activation state , 2001 .
[206] K. Fukase,et al. Muramyldipeptide and diaminopimelic acid‐containing desmuramylpeptides in combination with chemically synthesized Toll‐like receptor agonists synergistically induced production of interleukin‐8 in a NOD2‐ and NOD1‐dependent manner, respectively, in human monocytic cells in culture , 2004, Cellular microbiology.
[207] G. Dennert,et al. High Sensitivity of CD4+CD25+ Regulatory T Cells to Extracellular Metabolites Nicotinamide Adenine Dinucleotide and ATP: A Role for P2X7 Receptors1 , 2005, The Journal of Immunology.
[208] J. Hiscott,et al. Gene Expression and Antiviral Activity of Alpha/Beta Interferons and Interleukin-29 in Virus-Infected Human Myeloid Dendritic Cells , 2005, Journal of Virology.
[209] C. Riccardi,et al. GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily , 2005, European journal of immunology.
[210] C. Czuprynski,et al. Muramyl peptides augment the in vitro and in vivo cytostatic activity of canine plastic-adherent mononuclear cells against canine osteosarcoma cells. , 1993, Cancer biotherapy.
[211] D. Philpott,et al. Peptidoglycan Molecular Requirements Allowing Detection by Nod1 and Nod2* , 2003, Journal of Biological Chemistry.
[212] Jiun Wang,et al. CpG-Independent Synergistic Induction of β-Chemokines and a Dendritic Cell Phenotype by Orthophosphorothioate Oligodeoxynucleotides and Granulocyte-Macrophage Colony-Stimulating Factor in Elutriated Human Primary Monocytes1 , 2005, The Journal of Immunology.
[213] Douglas A. Hosack,et al. Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. , 2005, The Journal of clinical investigation.
[214] J. Sprent,et al. DNA as an Adjuvant: Capacity of Insect DNA and Synthetic Oligodeoxynucleotides to Augment T Cell Responses to Specific Antigen , 1998, The Journal of experimental medicine.
[215] Peter P. Nawroth,et al. Release of High Mobility Group Box 1 by Dendritic Cells Controls T Cell Activation via the Receptor for Advanced Glycation End Products1 , 2005, The Journal of Immunology.
[216] L. Kwak,et al. Toll-Like Receptor 4-Dependent Activation of Dendritic Cells by β-Defensin 2 , 2002, Science.
[217] R. North,et al. Increased toxicity of endotoxin for tumor-bearing mice and mice responding to bacterial pathogens: macrophage activation as a common denominator , 1980, Infection and immunity.
[218] O. Majdic,et al. B7-H1 (Programmed Death-1 Ligand) on Dendritic Cells Is Involved in the Induction and Maintenance of T Cell Anergy 1 , 2003, The Journal of Immunology.
[219] S. Kaveri,et al. Cutting Edge: Human CD4+CD25+ T Cells Restrain the Maturation and Antigen-Presenting Function of Dendritic Cells1 , 2004, The Journal of Immunology.
[220] S. Akira,et al. Antigenic Epitopes Fused to Cationic Peptide Bound to Oligonucleotides Facilitate Toll-Like Receptor 9-Dependent, but CD4+ T Cell Help-Independent, Priming of CD8+ T Cells1 , 2003, The Journal of Immunology.
[221] A. Rudensky,et al. Analysis of the Underlying Cellular Mechanisms of Anti-CD154-Induced Graft Tolerance: The Interplay of Clonal Anergy and Immune Regulation1 , 2005, The Journal of Immunology.
[222] Ross M. Kedl,et al. Immunization with HIV-1 Gag Protein Conjugated to a TLR7/8 Agonist Results in the Generation of HIV-1 Gag-Specific Th1 and CD8+ T Cell Responses , 2005, The Journal of Immunology.
[223] R. Wiltrout,et al. Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[224] T. Di Pucchio,et al. Potent Immune Response against HIV-1 and Protection from Virus Challenge in hu-PBL-SCID Mice Immunized with Inactivated Virus-pulsed Dendritic Cells Generated in the Presence of IFN-α , 2003, The Journal of experimental medicine.
[225] S. Sakaguchi. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. , 2004, Annual review of immunology.
[226] Setsuya Aiba,et al. Synergistic Effect of Nod1 and Nod2 Agonists with Toll-Like Receptor Agonists on Human Dendritic Cells To Generate Interleukin-12 and T Helper Type 1 Cells , 2005, Infection and Immunity.
[227] Yiming Shao,et al. Enhanced: The Need for a Global HIV Vaccine Enterprise , 2003, Science.
[228] C. Gabel,et al. Antimicrobial Peptides Initiate IL-1β Posttranslational Processing: A Novel Role Beyond Innate Immunity , 2002, The Journal of Immunology.
[229] J. Berzofsky,et al. Combined prophylactic and therapeutic cancer vaccine: Enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA‐A2 mice , 2006, International journal of cancer.
[230] S. Akira,et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus , 2005, The Journal of experimental medicine.
[231] Ji Ming Wang,et al. β-Defensins: Linking Innate and Adaptive Immunity Through Dendritic and T Cell CCR6 , 1999 .
[232] P. Musiani,et al. OX40 Ligand-Transduced Tumor Cell Vaccine Synergizes with GM-CSF and Requires CD40-Apc Signaling to Boost the Host T Cell Antitumor Response1 , 2003, The Journal of Immunology.
[233] D. Montefiori,et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. , 1999, Science.
[234] D. Philpott,et al. Synergistic stimulation of human monocytes and dendritic cells by Toll‐like receptor 4 and NOD1‐ and NOD2‐activating agonists , 2005, European journal of immunology.
[235] W. Bessler,et al. Cellular Recognition of Tri-/Di-palmitoylated Peptides Is Independent from a Domain Encompassing the N-terminal Seven Leucine-rich Repeat (LRR)/LRR-like Motifs of TLR2* , 2003, Journal of Biological Chemistry.
[236] Marc K Jenkins,et al. Visualizing the first 50 hr of the primary immune response to a soluble antigen. , 2004, Immunity.
[237] J. Ting,et al. CATERPILLER: a novel gene family important in immunity, cell death, and diseases. , 2005, Annual review of immunology.
[238] J. Kim,et al. HIV-1 DNA vaccines and chemokines. , 1999, Vaccine.
[239] I. Fidler,et al. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[240] K. Mohler,et al. CD40/CD40 ligand interactions are required for T cell‐dependent production of interleukin‐12 by mouse macrophages , 1996, European journal of immunology.
[241] A. Harris,et al. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. , 2004, The Journal of clinical investigation.
[242] R. Rappuoli,et al. What are the limits of adjuvanticity? , 2001, Vaccine.
[243] U. Andersson,et al. RAGE is the Major Receptor for the Proinflammatory Activity of HMGB1 in Rodent Macrophages , 2005, Scandinavian journal of immunology.
[244] R. Dubielzig,et al. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[245] J. Berzofsky,et al. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. , 2001, International immunology.
[246] P. Luciw,et al. Co-immunization of rhesus macaques with plasmid vectors expressing IFN-gamma, GM-CSF, and SIV antigens enhances anti-viral humoral immunity but does not affect viremia after challenge with highly pathogenic virus. , 2002, Vaccine.
[247] B. M. Flynn,et al. Role of CD8+ Lymphocytes in Control of Simian Immunodeficiency Virus Infection and Resistance to Rechallenge after Transient Early Antiretroviral Treatment , 2001, Journal of Virology.
[248] Christophe Caux,et al. A type I interferon autocrine–paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells , 2005, The Journal of experimental medicine.
[249] S. Akira,et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3 , 2006, Nature.
[250] Xiao-tong Song,et al. SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. , 2005, The Journal of clinical investigation.
[251] Ethan M. Shevach,et al. CD4+CD25+ suppressor T cells: more questions than answers , 2002, Nature Reviews Immunology.
[252] J. Kim,et al. Engineering of DNA vaccines using molecular adjuvant plasmids. , 2000, Developments in biologicals.
[253] H. Geng,et al. HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD‐1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma , 2006, International journal of cancer.
[254] J. Sprent,et al. An IFN-γ-Dependent Pathway Controls Stimulation of Memory Phenotype CD8+ T Cell Turnover In Vivo by IL-12, IL-18, and IFN-γ1 , 2001, The Journal of Immunology.
[255] L. Pease,et al. B7-DC cross-linking restores antigen uptake and augments antigen-presenting cell function by matured dendritic cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[256] T. Nomura,et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells , 2005, The Journal of experimental medicine.
[257] S. Paulie,et al. Antibodies to distinct epitopes on the CD40 molecule co-operate in stimulation and can be used for the detection of soluble CD40. , 1994, Immunology.
[258] R. Puri,et al. IL-13 signaling through the IL-13α2 receptor is involved in induction of TGF-β1 production and fibrosis , 2006, Nature Medicine.
[259] R. Steinman,et al. In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination , 2004, The Journal of experimental medicine.
[260] A. Lanzavecchia,et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation , 1996, The Journal of experimental medicine.
[261] S. Gregory,et al. Initial characterization of a lymphokine pathway for the immunologic induction of tumor necrosis factor-alpha release from human peripheral blood mononuclear cells. , 1988, Journal of immunology.
[262] G. Trinchieri,et al. The Reciprocal Interaction of NK Cells with Plasmacytoid or Myeloid Dendritic Cells Profoundly Affects Innate Resistance Functions1 , 2005, The Journal of Immunology.
[263] H. von Boehmer,et al. The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer. , 2006, Seminars in cancer biology.
[264] C. Figdor,et al. Dendritic cell immunotherapy: mapping the way , 2004, Nature Medicine.
[265] F. Eko,et al. Suppression of Endogenous IL-10 Gene Expression in Dendritic Cells Enhances Antigen Presentation for Specific Th1 Induction: Potential for Cellular Vaccine Development1 , 2000, The Journal of Immunology.
[266] S. Akira,et al. Regulation of dendritic cell function through toll-like receptors. , 2003, Current molecular medicine.
[267] B. Pulendran,et al. Cutting Edge: Different Toll-Like Receptor Agonists Instruct Dendritic Cells to Induce Distinct Th Responses via Differential Modulation of Extracellular Signal-Regulated Kinase-Mitogen-Activated Protein Kinase and c-Fos 1 , 2003, The Journal of Immunology.
[268] C. Barker,et al. THE ROLE OF AFFERENT LYMPHATICS IN THE REJECTION OF SKIN HOMOGRAFTS , 1968, The Journal of experimental medicine.
[269] Stefanie Schlemminger,et al. Hepatitis A Virus Suppresses RIG-I-Mediated IRF-3 Activation To Block Induction of Beta Interferon , 2005, Journal of Virology.
[270] G. Freeman,et al. Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.
[271] M. Wewers. IL-1β: An endosomal exit , 2004 .
[272] F. Vogel. Improving vaccine performance with adjuvants. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[273] A. Freeman,et al. Pharmacologic effects of polyinosinic• polycytidylic acid in man , 1977, Journal of medical virology.
[274] Gary J. Nabel,et al. The need for a global HIV vaccine enterprise. Policy forum. , 2003 .
[275] L. Joosten,et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. , 2006, The Journal of clinical investigation.
[276] M. Wewers,et al. A Novel P2X7 Receptor Activator, the Human Cathelicidin-Derived Peptide LL37, Induces IL-1β Processing and Release1 , 2004, The Journal of Immunology.
[277] T. Sugie,et al. Immunosuppression by CD4+ regulatory T cells induced by chronic retroviral infection , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[278] B. Rouse,et al. CD4+ CD25+ T Cells Regulate Vaccine-Generated Primary and Memory CD8+ T-Cell Responses against Herpes Simplex Virus Type 1 , 2004, Journal of Virology.
[279] S. Ziegler,et al. Cutting Edge: Anti-CD25 Monoclonal Antibody Injection Results in the Functional Inactivation, Not Depletion, of CD4+CD25+ T Regulatory Cells1 , 2006, The Journal of Immunology.
[280] D. Philpott,et al. NACHT-LRR proteins (NLRs) in bacterial infection and immunity. , 2005, Trends in microbiology.
[281] S. Akira,et al. Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8 , 2004, Science.
[282] D. Weiner,et al. Enhancement of human immunodeficiency virus type 1‐DNA vaccine potency through incorporation of T‐helper 1 molecular adjuvants , 2004, Immunological reviews.
[283] F. Martinon,et al. NALPs: a novel protein family involved in inflammation , 2003, Nature Reviews Molecular Cell Biology.
[284] N. Kadowaki,et al. Subsets of Human Dendritic Cell Precursors Express Different Toll-like Receptors and Respond to Different Microbial Antigens , 2001, The Journal of experimental medicine.
[285] A. Di Nardo,et al. Augmentation of cutaneous immune responses by ATPγS: purinergic agonists define a novel class of immunologic adjuvants , 2008, The Journal of Immunology.
[286] S. Yokoyama,et al. Enhancement of endotoxin activity by muramyldipeptide. , 2002, Journal of endotoxin research.
[287] Tae Woo Kim,et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. , 2003, The Journal of clinical investigation.
[288] C. Spina,et al. Multimeric Soluble CD40 Ligand and GITR Ligand as Adjuvants for Human Immunodeficiency Virus DNA Vaccines , 2006, Journal of Virology.
[289] L. Rollins,et al. An Alternative and Effective HIV Vaccination Approach Based on Inhibition of Antigen Presentation Attenuators in Dendritic Cells , 2006, PLoS medicine.
[290] N. Kendrick,et al. ATP-induced killing of mycobacteria by human macrophages is mediated by purinergic P2Z(P2X7) receptors. , 1997, Immunity.
[291] I. M. Belyakov,et al. Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines. , 2003, Current molecular medicine.
[292] S. Lonial,et al. A randomized, placebo-controlled trial of subcutaneous administration of GM-CSF as a vaccine adjuvant: effect on cellular and humoral immune responses. , 2002, Vaccine.